浸润性髓系细胞通过GRM4调控IL23驱动骨肉瘤进展
该研究利用Grm4基因敲除小鼠和骨肉瘤条件培养基,发现GRM4在髓系细胞中选择性调控IL23与IL12表达,骨肉瘤中IL23:IL12比值升高且高IL23与患者生存更差相关,IL23敲除小鼠抵抗骨肉瘤发生,GRM4激动剂或IL23中和抗体可抑制小鼠骨肉瘤生长,提示GRM4-IL23/IL12轴是可干预的髓系抑制通路。
要点
- GRM4在髓系细胞中调控IL23/IL12轴,驱动骨肉瘤进展。
- 人骨肉瘤IL23:IL12比值升高,高IL23表达与更差生存相关。
- GRM4激动剂或IL23中和抗体在小鼠中抑制骨肉瘤生长。
核心结论
- GRM4通过髓系细胞非细胞自主机制调控IL23,驱动骨肉瘤进展,该通路具可成药性。
研究设计与样本
- 研究采用Grm4-/-基因靶向小鼠,并与Rb1+/-小鼠比较辐射诱导肿瘤发生。
- 研究使用骨肉瘤条件培养基处理髓系细胞,检测Il23与Il12表达。
- 研究分析人和小鼠骨肉瘤中IL23与IL12表达及人IL23表达与生存的关系。
- 研究使用Il23-/-小鼠评估骨肉瘤发生,并用GRM4激动剂或IL23中和抗体处理小鼠。
主要发现
- Grm4-/-小鼠辐射诱导肿瘤发生加速,程度与Rb1+/-小鼠相当。
- GRM4表达于髓系细胞,选择性调控IL23及相关细胞因子IL12表达。
- 骨肉瘤条件培养基以GRM4依赖方式诱导髓系细胞Il23表达,同时抑制Il12。
- 人和小鼠骨肉瘤均表达升高的IL23:IL12比值,人高IL23表达与更差生存相关。
- Il23-/-小鼠对骨肉瘤发生显著抵抗,GRM4激动剂或IL23中和抗体抑制小鼠骨肉瘤生长。
临床怎么用
- GRM4-IL23/IL12轴可作为骨肉瘤潜在治疗靶点,GRM4激动剂或IL23中和抗体值得进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The glutamate metabotropic receptor 4 (GRM4) locus is linked to susceptibility to human osteosarcoma, through unknown mechanisms. We show that Grm4-/- gene-targeted mice demonstrate accelerated radiation-induced tumor development to an extent comparable with Rb1+/- mice. GRM4 is expressed in myeloid cells, selectively regulating expression of IL23 and the related cytokine IL12. Osteosarcoma-conditioned media induce myeloid cell Il23 expression in a GRM4-dependent fashion, while suppressing the related cytokine Il12. Both human and mouse osteosarcomas express an increased IL23:IL12 ratio, whereas higher IL23 expression is associated with worse survival in humans. Consistent with an oncogenic role, Il23 -/- mice are strikingly resistant to osteosarcoma development. Agonists of GRM4 or a neutralizing antibody to IL23 suppressed osteosarcoma growth in mice. These findings identify a novel, druggable myeloid suppressor pathway linking GRM4 to the proinflammatory IL23/IL12 axis. SIGNIFICANCE: Few novel systemic therapies targeting osteosarcoma have emerged in the last four decades. Using insights gained from a genome-wide association study and mouse modeling, we show that GRM4 plays a role in driving osteosarcoma via a non-cell-autonomous mechanism regulating IL23, opening new avenues for therapeutic intervention.See related commentary by Jones, p. 1484.This article is highlighted in the In This Issue feature, p. 1469.
引用
- Kansara M, Thomson K, Pang P, et al. Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. Cancer Discov. 2019. PMID: 31527131. doi:10.1158/2159-8290.CD-19-0154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。